Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof-of-Concept, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®

NCT02722122 is registered in ClinicalTrials.gov with Protalix as lead sponsor.

NCT NCT02722122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02722122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof-of-Concept, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®
Lead sponsor
Protalix
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2016
Completion date
Not reported
Enrollment
15 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis